Indonesua will attest to effectiveness of sinovac before it was even approved. UAE own shares in the maker of this vaccine.
A real-world study of millions of Chileans who received CoronaVac found it 65% effective against symptomatic COVID-19, 87% against hospitalization, 90% against ICU admissions, and 86% against deaths.[14] In Indonesia, real world data showed 94% of inoculated health care workers protected against symptomatic infection by the vaccine, beating results in clinical trials.[15] Phase III results from Brazil had previously showed 50.7% efficacy at preventing symptomatic infections and 83.7% effective in preventing mild cases needing treatment.[16] Final Phase III results from Turkey announced on 3 March 2021 showed an efficacy of 84%.[17]
Politicization, transparency issues and some incomplete trial data in Brazil contributed to a lack of trust in CoronaVac there.[18][19]